Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.
As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential.
Aspen has a strong global presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries. The Group has 26 manufacturing facilities at 18 sites across 6 continents and has more than 10 000 employees.
Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.
Aspen’s half year gross revenue surged by 47% to R19 billion. CNBC Africa’s David Williams chatted with Aspen Group Chief Executive Stephen Saad about the results.